The Globe and Mail reports in its Friday, June 16, edition that CIBC World Markets analyst John Zamparo has reaffirmed his "neutral" recommendation for Aurora Cannabis. The Globe's David Leeder writes in the Eye On Equities column that Mr. Zamparo cut his share target back by 75 cents to $1. Analysts on average target the shares at $1.42. Mr. Zamparo says in a note: "We are maintaining our 'neutral' rating on Aurora Cannabis while reducing our price target to reflect lower sales forecasts and even more restrained sentiment for cannabis stocks. Aurora's incremental $40-million in planned cost cuts will be necessary to achieve true profitability, which is ultimately required to attract investors. Aurora trades at just 0.7 times sales and 11 times EBITDA (on NTM figures). While this compares favourably to peers, we expect valuation will not be given credit until positive FCF is attained, which isn't expected until late 2024." The Globe reported on Sept. 23 that ATB Capital's Frederico Gomes raised Aurora to "sector perform," from "underperform." The shares could then be had for $1.66. The Globe reported on Feb. 13 that Canaccord Genuity analyst Matt Bottomley rated Aurora "hold." It was then worth $1.22.